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Abstract
Objective To examine the association between alcohol
consumption, cigarette smoking, and endometrial cancer.
Methods In 1986, the Netherlands Cohort Study was
initiated. A self-administered questionnaire on dietary
habits and other cancer risk factors was completed by
62,573 women. Follow-up for cancer was established by
record linkage to the Netherlands Cancer Registry.
Results After 11.3-years of follow-up, 280 incident
endometrial cancer cases were available for analyses. In
multivariate analysis, the rate ratio (RR) for alcohol users
versus non-users was 1.06 (95% Conﬁdence Interval (95%
CI) = 0.78–1.43). There were neither dose-dependent
trends nor associations with different types of beverages.
The RR for former and current smokers versus never-
smokers was 0.83 (95% CI = 0.58–1.20) and 0.59 (95%
CI = 0.40–0.88), respectively. These estimates did not
change signiﬁcantly when body mass index (BMI) and age
at menopause were added to the models.
Conclusions There is no association between alcohol
consumption and endometrial cancer. Current smoking is
associated with a reduced risk of endometrial cancer. This
association is neither mediated by BMI nor by age at
menopause.
Keywords Alcohol drinking  Smoking  Endometrial
neoplasms  Cohort studies  Netherlands
Introduction
Endometrial cancer is the most frequently diagnosed
gynecologic cancer in Europe [1]. The development of
endometrial cancer has been related to exposure to estro-
gens unopposed by progestagens [2]. Many studies have
shown a positive association between alcohol ingestion
and estrogen levels in postmenopausal women. For in-
stance, cross-sectional data from the European Prospective
Investigation into Cancer and Nutrition (EPIC) suggested
that elevated blood levels of estrone are observed with
increasing alcohol consumption in postmenopausal women
[3]. Thus, alcohol could be expected to increase endo-
metrial cancer risk by elevating estrogen levels. An
important determinant of estrogen levels in women is use
of unopposed hormone replacement therapy (HRT).
Accordingly, use of unopposed HRT is consistently
associated with an increased risk of endometrial cancer
[4–6]. Furthermore, it has been suggested that alcohol
consumption increases estradiol levels in particular in
postmenopausal women who are on HRT [7, 8]. However,
previous studies have indicated that alcohol consumption
is either weakly or not associated with a reduced risk of
endometrial cancer and no signiﬁcant interaction with use
of HRT has been found [9]. Although several studies have
analyzed the association between alcohol consumption and
endometrial cancer risk [10–22], only few studies have
examined the risk associated with various measures of
alcohol consumption (e.g., amount and type of alcohol)
including only one comprehensive prospective cohort
study [18].
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to exert anti-estrogenic effects [23] and to lower the risk
of endometrial cancer in this way. Also, an effect modiﬁ-
cation by use of HRT seems reasonable [24]. Furthermore,
it has been suggested that body mass index (BMI) and age
at menopause might mediate part of the inverse association
between smoking and endometrial cancer [24]. Earlier
prospective studies [22, 25–29] have generally suggested
that smoking is associated with a slight to moderate
protection against endometrial cancer. However, to date,
only the largest and most recent prospective cohort study
has reported a signiﬁcantly reduced risk in both current and
past smokers [29]. Moreover, this large study explored
the relationship between HRT and smoking and found no
effect-modiﬁcation, and also found that the association
between smoking and endometrial cancer was not con-
founded by alcohol use [29]. The evidence from
other epidemiological studies with regard to an effect-
modiﬁcation by use of HRT is ambiguous [24].
As many case–control [24], but only a few cohort
studies have reported on the association between smoking
and endometrial cancer [22, 25–29], the International
Agency for Research on Cancer concludes that prospective
cohort studies, in which selection and recall bias are
minimized, are scarce [30]. Only two cohort studies have
explored the association between smoking and endometrial
cancer comprehensively by examining the risk associated
with all common quantitative smoking measures (e.g.,
smoking duration, time since cessation) [28, 29].
Since only few prospective cohort studies have investi-
gated the association between alcohol consumption, ciga-
rette smoking, and endometrial cancer comprehensively,
important features of this relationship are under-explored.
Hence, we aim to provide additional evidence based on
prospective data. Moreover, we intend to elucidate the
hormonal mechanisms underlying endometrial carcino-
genesis by investigating, ﬁrst, whether BMI and age at
menopause might act as intermediary variables in the
association between smoking and endometrial cancer and
by examining, second, whether there is evidence regarding
a potential effect modiﬁcation by HRT use.
Materials and methods
The Netherlands Cohort Study (NLCS) started in
September 1986 when 62,573 women aged 55–69 years
were enrolled in the cohort. Ethical approval was obtained
from the ethics committee of the University Hospital
Maastricht. All women were presumed to be postmeno-
pausal. At baseline, data on dietary habits and other risk
factors (such as alcohol consumption, smoking history,
reproductive history, and anthropometry) were collected by
means of a self-administered questionnaire. Data analysis
was conducted according to the case–cohort approach. In
this approach, cases are derived from the cohort (providing
numerator information for the incidence rates), while the
accumulated person-years at risk of the cohort are esti-
mated from a random sample from the cohort, i.e., the
subcohort (providing denominator information for the
incidence rates). Following this approach, a subcohort of
2,589 women was sampled after the baseline exposure
measurement. The subcohort has been followed up bien-
nially by mail for vital status information. The vital status
of subcohort members, who did not respond was completed
by contacting the municipal population registers. Incident
cases occurring in the entire cohort were detected by an-
nual record linkages to the Netherlands Cancer Registry
and the nationwide network and registry of histopathology
and cytopathology in the Netherlands (PALGA). Further
details on the design of the study and methods of follow-up
have been presented elsewhere [31, 32].
The present analysis is restricted to cancer incidence in
the 11.3-year follow-up period from September 1986 to
December 1997. The completeness of cancer follow up was
estimated to be at least 96% [33], and no subcohort
members were lost to follow up.
Three hundred and twenty-seven incident, microscopi-
cally conﬁrmed, invasive, primary endometrial carcinomas
were detected after a follow-up period of 11.3 years. Cases
were excluded from analysis if they had been diagnosed
with non-epithelial tumors (n = 12), and if information on
either alcohol consumption or cigarette smoking was
incomplete (n = 35).
Women were eligible for the subcohort if they did not
report at baseline that they had undergone hysterectomy.
Application of this inclusion criterion yielded a subcohort
of 2,229 members. Individuals were excluded from the
analysis if they had been diagnosed with cancer other than
skin cancer at baseline (n = 151) and if information on
either alcohol consumption or cigarette smoking was
missing (n = 177). After these exclusions, 280 cases and
1,901 subcohort members remained available for analysis.
Questionnaire data
Consumption of alcoholic beverages during the year
preceding the baseline interview was assessed by con-
sumption frequency questions on beer, red wine, white
wine, sherry, other fortiﬁed wine, liqueur, and liquor.
Categories ranked from ‘never’ to ‘6–7 times per week’
and information on the number of glasses per consumption
day was also requested. Questionnaire data of all cases
and subcohort members were key entered twice and pro-
cessed in a manner blinded with regard to case/subcohort
status in order to minimize observer bias in the coding and
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123interpretation of data. The questionnaire has been validated
against a nine-day diet record [34, 35]. The Pearson
correlation coefﬁcient between the mean daily ethanol
intake assessed by the questionnaire and that estimated by
the nine-day record was 0.86 for all subjects and 0.78 for
users of alcoholic beverages [34]. Respondents that re-
ported to drink alcohol less than once per month were
considered non-drinkers. Four items from the questionnaire
(red wine, white wine, sherry, and liqueur) were combined
into one single wine variable since these items were highly
correlated and separate analysis would have resulted in
small numbers of subjects within each stratum. Mean daily
alcohol consumption was calculated using the Dutch food
composition table [36]. Based on data from a pilot study,
standard glasses were deﬁned as follows: 200 ml for beer,
105 ml for wine, 80 ml for sherry, and 45 ml for both
liqueur and liquor, corresponding to 8 g, 10 g, 11 g, 7 g,
and 13 g of alcohol, respectively.
Smoking was addressed at baseline by questions on age
at ﬁrst exposure to smoking, age at last exposure to
smoking, smoking frequency, and smoking duration of
cigarette, cigar, and pipe smokers. As the vast majority of
smoking subcohort members was cigarette smokers, anal-
yses were restricted to that particular group. Based on the
questionnaire data, the following cigarette smoking vari-
ables were constructed: cigarette smoking status (never
versus ever and never versus former or current), frequency
(number of cigarettes per day), duration (years), age at ﬁrst
exposure (years), and time since cessation (years). Time
since cessation was calculated as ‘age at baseline’ minus
‘age at smoking cessation’.
Concerning the use of HRT, women were asked whether
they hadever usedHRTbecauseofcomplaintsrelatedtothe
menopause. We can assume that all members of our cohort
were postmenopausal in 1986, when the baseline ques-
tionnaires were completed, and that possible treatment with
HRT took place prior to 1986 in most women. Based on
information regarding HRT prescription in the Netherlands
in the past [37–39], we assume that all HRT users enrolled
in the NLCS were treated with unopposed oral estrogens.
Data analysis
A variable was considered a confounder if (I) it was
associated with endometrial cancer risk, if (II) it was
associated with alcohol consumption or cigarette smoking,
and if (III) age-adjusted hazard ratios changed by more
than 10% after adjustment for the potentially confounding
factor. Based on the literature [40] and previous analyses,
we considered the following variables as potential con-
founders: age (continuous), age at menarche (continuous),
use of oral contraceptives (ever versus never), duration of
oral contraceptive use (continuous), age at ﬁrst child birth
(continuous), parity (continuous), age at menopause (con-
tinuous), use of postmenopausal hormones (ever versus
never), duration of postmenopausal hormone use (contin-
uous), non-occupational physical activity (categorized),
BMI (continuous), height (continuous), energy intake
(continuous), total fat intake (continuous), intake of satu-
rated fat (continuous), intake of carbohydrates (continu-
ous), intake of dietary ﬁber (continuous), intake of
vegetables (continuous), intake of fruits (continuous),
coffee consumption (yes versus no), education (catego-
rized), diagnosis of hypertension (yes versus no), diagnosis
of diabetes mellitus (yes versus no), family history of
endometrial cancer (yes versus no), and if applicable: total
alcohol consumption per day (continuous), type of alco-
holic beverage (categorized), current smoking (yes versus
no), number of cigarettes smoked per day (continuous), and
duration of smoking (continuous).
Incidence rate ratios (RR) and corresponding 95 percent
conﬁdence intervals (95% CI) for endometrial cancer were
estimated in the age-adjusted and multivariate case–cohort
analyses with categorized and continuous alcohol and
cigarette smoking variables, using the Cox proportional
hazards model [41] processed with the Stata statistical
software package [42]. Standard errors were estimated
using the robust Hubert–White sandwich estimator to
account for additional variance introduced by sampling
from the cohort. This method is equivalent to the variance–
covariance estimator by Barlow [43]. The proportional
hazards assumption was tested using the scaled Schoenfeld
residuals [44]. Tests for dose-response trends in risk of
endometrial cancer were assessed by ﬁtting ordinal expo-
sure variables as continuous terms. Tests for interaction
were performed by using the Wald test. Two-sided p values
are reported throughout the paper.
Results
The percentage of women reporting alcohol consumption
was similar among cases and subcohort members (67.5%
and 66.9%, respectively), as was the mean alcohol
consumption per day among users in both groups (7.7 g
with standard deviation (sd) = 10.8, and 8.5 g (sd = 10.4),
respectively). Current smoking was less prevalent among
cases than among subcohort members (15.4% vs. 21.8%),
but the number of cigarettes smoked per day did not
differ considerably between smokers in both groups (13.6
(sd = 8.4) and 13.2 (sd = 8.1), respectively).
Drinkers reported a slightly higher age at menopause
and a higher prevalence of both oral contraceptive use
and current cigarette smoking than non-drinkers (see
Table 1). With regard to smoking status, former and cur-
rent smokers were slightly leaner and had fewer children
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123than never-smokers. On average, current smokers reported
having reached menopause 1 year earlier than former-
smokers and never-smokers. The prevalence of both oral
contraceptive use and alcohol use was higher among
smokers than among never-smokers. Also, average alcohol
consumption was approximately twice as high among
smokers as among never-smokers (see Table 1).
Based on the literature and based on the methodological
criteria speciﬁed above, we found the following con-
founders: age, BMI, parity, oral contraceptive use, non-
occupational physical activity, hypertension, age at ﬁrst
child birth, and age at menopause. Alcohol consumption
and cigarette smoking status were found to confound each
other’s association with endometrial cancer. We controlled
for all these confounders in multivariate analyses. In
additional analyses, we mutually controlled the age-
adjusted risk estimates regarding qualitative smoking
measures for the other smoking measures.
The multivariate risk estimates did not change sub-
stantially when oral contraceptive use (ever/never) was
replaced by duration of oral contraceptive use (data not
shown). Accordingly, we considered it sufﬁcient to control
only for oral contraceptive use (ever/never).
Table 2 shows the results for the association between
alcohol consumption and endometrial cancer. The multi-
variate adjusted RR associated with alcohol consumption
was 1.06 (95% CI = 0.78–1.43). The multivariate RRs of
endometrial cancer for women who consumed up to 4, 5–
14, 15–29, and 30 or more gram of alcohol per day versus
non-drinkers were 1.09 (95% CI = 0.78–1.52), 0.95 (95%
CI = 0.62–1.45), 0.94 (95% CI = 0.52–1.69), and 1.78
(95% CI = 0.88–3.60), respectively. No signiﬁcant trend
was observed (ptrend = 0.62).
The multivariate RR of endometrial cancer for wine-
consumers versus non-consumers was slightly, but non-
signiﬁcantly, elevated (RR = 1.13, 95% CI = 0.84–1.52).
The RRs were also slightly, but non-signiﬁcantly elevated
when calculated according to different levels of wine
consumption and no signiﬁcant trend was observed
(ptrend = 0.64). The multivariate RR of endometrial cancer
associated with drinking beer equaled 1.30 (95%
CI = 0.82–2.07) and the RR for drinking liquor was 1.11
(95% CI = 0.73–1.68).
Regarding smoking, age-adjusted analysis revealed an
inverse association between ever-smoking and endometrial
cancer risk (RR = 0.70, 95% CI = 0.54–0.92, see Table 3).
Table 1 Means (standard deviation) and distribution (n) of potential confounders according to alcohol consumption and cigarette smoking status
among subcohort members, the Netherlands Cohort Study (1986–1995)
Characteristic Unit Alcohol consumption status Cigarette smoking status
No
(n = 630)
Yes
(n = 1,271)
Never
(n = 1,100)
Former
(n = 387)
Current
(n = 414)
Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd)
Age Years 61.8 (4.3) 61.4 (4.3) 62.0 (4.3) 61.1 (4.4) 60.7 (4.1)
Body Mass Index kg/m
2 25.4 (3.9) 24.9 (3.4) 25.3 (3.5) 24.7 (3.3) 24.6 (3.8)
Parity Number of
children
2.8 (2.4) 2.7 (2.2) 3.0 (2.4) 2.5 (1.8) 2.5 (2.1)
Age at 1st child birth Years 22.0 (11.2) 21.9 (11.3) 22.2 (11.2) 22.3 (11.3) 20.8 (11.3)
Age at menopause Years 48.3 (4.8) 49.2 (4.3) 49.1 (4.4) 49.2 (4.1) 48.1 (4.8)
Total energy intake (including
alcohol)
kcal 1,628 (415) 1,724 (386) 1,694 (393) 1,676 (406) 1,705 (406)
Alcohol consumption G/day 0 (0) 8.5 (10.4) 5.7 (7.8) 10.4 (11.2) 12.5 (12.8)
Cigarettes No./day 13.0 (8.8) 11.1 (8.1) 0 (0) 9.8 (8.0) 13.2 (8.1)
n (%)
a n (%)
a n (%)
a n (%)
a n (%)
a
Oral contraceptive use Ever 124 (20.0) 336 (26.7) 223 (20.6) 127 (32.9) 110 (26.8)
Physical activity >30 min/day 425 (69.1) 975 (77.8) 796 (74.1) 306 (79.5) 298 (72.9)
Diagnosis of hypertension Yes 198 (31.4) 351 (27.6) 339 (30.8) 107 (27.7) 103 (24.9)
Diagnosis of diabetes Yes 33 (5.2) 40 (3.2) 48 (4.4) 13 (3.4) 12 (2.9)
Hormone replacement therapy Ever 62 (10.0) 152 (12.1) 107 (9.9) 58 (15.1) 49 (12.0)
Family history of endometrial cancer Yes 20 (3.2) 32 (2.5) 23 (2.1) 16 (4.1) 13 (3.1)
Alcohol users Yes – – 663 (60.3) 312 (80.6) 296 (71.5)
Currently smoking cigarettes Yes 118 (18.7) 296 (23.3) – – –
a The percentage reported for some variables does sometimes not correspond with the numbers per smoker stratum since part of the information
for these variables was missing
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123We observed signiﬁcant inverse trends of endometrial
cancer risk with all quantitative smoking measures. How-
ever, these trends became non-signiﬁcant when never-
smokers were excluded. Some of these age-adjusted risk
estimates changed substantially after additional adjustment
for current smoking status, smoking frequency and smok-
ing duration (see Table 3).
When we adjusted for all confounders, multivariate
analysis showed a statistically signiﬁcant 29% reduced risk
of endometrial cancer for ever-smokers when contrasted
with never-smokers. When considered separately, the risk
reduction appeared to be stronger among current smokers
(RR = 0.59, 95% CI = 0.40–0.88) than among former
smokers (RR = 0.83, 95% CI = 0.58–1.20). Tests for
trends were not signiﬁcant for any of the quantitative
smoking variables when these were adjusted for age and
additional confounders.
The strongest reduction in risk, which could be observed
in both univariate and multivariate models, was associated
with a smoking history of 40 or more years compared with
having never smoked (RR = 0.37, 95% CI = 0.15–0.90).
Moreover, we observed a non-signiﬁcant 50% reduction in
risk in women that quit smoking either nine or less years
ago or that quit 10–19 years ago. The data indicated no
association between age at ﬁrst smoking exposure and
endometrial cancer.
Omitting age at menopause and BMI from the multi-
variate models either separately or simultaneously did not
cause meaningful changes in the corresponding estimates.
No interactions in determining endometrial cancer risk
could be observed between alcohol consumption and HRT
use (p = 0.43), BMI (p = 0.38), age at menopause
(p = 0.39), or current cigarette smoking (p = 0.83). When
we stratiﬁed multivariate alcohol analyses according to
smoking status, we observed a non-signiﬁcantly lower risk
of endometrial cancer among alcohol consumers that
have ever smoked (RR = 0.91, 95% CI = 0.52–1.58)
than among alcohol consumers that have never smoked
(RR = 1.16, 95% CI = 0.81–1.67). Concerning smoking
and HRT use, the interaction term was not statistically
signiﬁcant (p = 0.11). In this subset analysis, current
smoking was associated with a reduced risk of endometrial
cancer in women not using HRT (RR = 0.54, 95%
CI = 0.35–0.84). In current smokers that did use HRT,
the RR was 1.32 (95% CI = 0.57–3.04). Numbers were
very small however: only 28 women were current smokers
and used HRT and only eight women were current smokers
and did not use HRT.
Table 2 Rate ratios of endometrial cancer according to baseline alcohol consumption in the Netherlands Cohort Study, 1986–1997
Alcohol consumption
(g/ day)
Age adjusted Multivariate adjusted
Categorical median Cases Person-years
in subcohort
RR (95% CI)
a Cases Person-years
in subcohort
RR (95% CI)
b
Total alcohol
No 0 91 6,641 1 (ref.) 82 5,837 1 (ref.)
Yes 4.0 189 13,746 1.01 (0.77–1.32) 172 12,137 1.06 (0.78–1.43)
0.1–4 1.6 114 7,599 1.10 (0.82–1.48) 105 6,643 1.09 (0.78–1.52)
5–14 9.1 47 3,640 0.94 (0.65–1.37) 39 3,279 0.95 (0.62–1.45)
15–29 20.9 17 1,822 0.69 (0.40–1.18) 17 1,575 0.94 (0.52–1.69)
‡30 37.3 11 684 1.20 (0.62–2.34) 11 639 1.78 (0.88–3.60)
p trend 0.49 0.62
Alcohol from wine
Yes 3.2 182 13,009 1.06 (0.81–1.37) 166 11,507 1.13 (0.84–1.52)
0.1–4 1.5 125 8,072 1.17 (0.88–1.55) 112 7,113 1.16 (0.84–1.59)
5–14 8.9 38 3,146 0.91 (0.61–1.36) 35 2,784 1.07 (0.68–1.67)
‡15 21.8 19 1,791 0.80 (0.48–1.35) 19 1,611 1.11 (0.64–1.93)
p trend 0.43 0.64
Alcohol from beer
Yes 1.14 29 1,873 1.15 (0.76–1.74) 26 1,629 1.30 (0.82–2.07)
Alcohol from liquor
Yes 3.7 34 2,648 0.93 (0.64–1.37) 31 2,349 1.11 (0.73–1.68)
a RR = rate ratios; CI = conﬁdence interval; n.a. = not applicable
b Rate ratios adjusted for age (years), body mass index (kg/m
2), parity (number of children), use of oral contraceptives (ever versus never), non-
occupational physical activity (low, moderate, active, very active), hypertension (yes versus no), age at ﬁrst child birth (years), age at menopause
(years), and current cigarette smoking (yes versus no)
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123Discussion
Our results do not suggest a meaningful association
between alcohol consumption and endometrial cancer risk.
Current smoking is associated with a reduced risk of
endometrial cancer. This inverse relationship is neither
mediated by BMI nor by age at menopause.
Regarding the biological mechanism underlying endo-
metrial carcinogenesis, the so-called ‘‘unopposed estrogen
hypothesis’’ is widely accepted [2]. According to this
hypothesis endometrial cancer develops when the endo-
metrium is exposed to high levels of unopposed endoge-
nous or exogenous estrogens for a long period of time. This
exposure results in elevated mitotic proliferation of
endometrial cells which, in turn, increases the risk of DNA
replication errors and DNA mutations which can lead to
endometrial cancer [2].
Although female alcohol consumers could be expected to
be at increased risk of endometrial cancer due to their
hormonal proﬁle, we have not detected signiﬁcant associa-
tions between alcohol consumption and endometrial cancer
risk. This ﬁnding is consistent with the vast majority of
previous studies [13, 15–18]. However, in the EPIC study,
signiﬁcantly elevated blood estrone levels were found only
inpostmenopausalwomenwhoconsumedmorethan25 gof
alcohol per day compared to non-drinkers [3]. Thus, possi-
bly, a marked increase in estrone concentrations, and
ultimately in endometrial cancer risk, can only be observed
in women who consume more than moderate amounts. This
notion might be supported by our data as we have observed
an (non-signiﬁcantly) elevated risk of endometrial cancer in
women who reported to drink more than 30 g of alcohol per
day. Based on literature reviews [7, 8], we hypothesized that
we might ﬁnd a positive association between alcohol
consumption and endometrial cancer risk in particular
among HRT users. However, our ﬁndings do not support the
hypothesisofaneffect-modiﬁcationbyHRTuse;neitherdid
most of the previous epidemiological studies [13, 17, 18].
Concerning smoking, an anti-estrogenic effect has been
suggested [23], which should lower the risk of endometrial
cancer according to the unopposed estrogen hypothesis.
Accordingly, our data indicated a signiﬁcant risk reduction
in current smokers, just like the Nurses’ Health Study did,
which has reported a RR of 0.72 (95% CI = 0.57–0.90) for
current smokers [29]. In contrast, other cohort studies have
observed non-signiﬁcant associations [25, 26, 28]. We
found that the inverse association between smoking and
endometrial cancer was more pronounced among current
smokers than among former smokers. These ﬁndings are in
linewiththeevidencefromseveralcase–control[17,45–47]
and two cohort studies [26, 28] and they suggest that the
degree of protection might partly depend on the time since
smoking cessation.
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123Although not statistically signiﬁcant, our prospective
data support this notion, because we observed that endo-
metrial cancer risk is possibly higher in women that quit
smoking 20 or more years ago compared to the risk in
women that quit 19 years ago or less. In the epidemio-
logical literature, a few studies presented data on time since
cessation [17, 28, 29, 48–50], but only one of them found a
signiﬁcantly lowered risk among women that quit smoking
less than 10 years ago [48].
Considering the risk associated with duration of smok-
ing, we have observed a reduction in risk with a long
smoking history, just like previous studies [17, 29, 47, 48].
With regard to smoking intensity, we have found that
smoking 20 or more cigarettes per day is associated with a
non-signiﬁcantly elevated risk of endometrial cancer.
Though one needs to bear in mind that the corresponding
conﬁdence intervals were large, these point estimates are
possibly not in line with the majority of previous studies,
whichgenerallyindicatedthatahighsmokingintensity(e.g.,
smoking 20 or more cigarettes per day) is associated with a
decreased risk of endometrial cancer [17, 22, 28, 29, 45, 47,
48, 51].This inconsistencycouldbe explainedby the lackof
adjustment for other smoking variables in earlier studies:
only one [29] out of six [22, 25–29] prospective cohort
studies has adjusted its smoking frequency estimates for the
potentially confounding effects of smoking duration. When
we omitted smoking duration from our multivariate models,
the RRs for smoking frequency also suggested an inverse
association with endometrial cancer (data not shown).
Our results do not indicate any important association
between the age at starting smoking and endometrial
cancer risk. Four previous studies [26, 28, 47, 49] found a
(non-signiﬁcant) risk reduction with young age at ﬁrst
exposure, that is, starting to smoke between age 15 [28] or
age 20 or earlier [49], but none of these studies has
reported a signiﬁcant trend.
It has been hypothesized that smoking might lower the
levels of estrogens partly by reducing the amount of fat
tissue or by decreasing the age at menopause [24]. In our
cohort, smokers were slightly leaner than non-smokers
(24.6 kg/m
2 vs. 25.3 kg/m
2). Moreover, on average, current
smokers appeared to have reached menopause 1 year earlier
than never-smokers and former smokers (48.1 years vs.
49.1 years). However, in conclusion, our analyses indicated
that BMI and age at menopause are no mediating factors.
In contrast to smoking, use of unopposed HRT increases
endometrial cancer risk in postmenopausal women.
Although an interaction between smoking and HRT use
seems biologically plausible, the small numbers in our
analysis did not allow to draw ﬁrm conclusions regarding a
possible effect modiﬁcation by HRT use. Moreover, we
had no precise information on what type of HRT women in
the NLCS have used. If we could have included such
information in our analysis, results might differ according
to type of HRT used.
Another potential drawback of our study might be mis-
classiﬁcation of self-reported alcohol consumption and/or
self-reported cigarette smoking. However, these misclassi-
ﬁcations might be non-differential owing to the prospective
study design. Consequently, the risk estimates would prob-
ably be biased towards no effect. Moreover, the correlation
between the alcohol consumption measured by the NLCS
questionnaire and themeasurementina nine-day recordwas
high due to the large variation in alcohol consumption [34].
An important strength of our study is that the exposures
were assessed prior to the diagnosis of endometrial cancer.
Therefore, our ﬁndings cannot be inﬂuenced by recall bias.
Moreover, selection bias is unlikely as the follow-up of
subcohort membersand cases was almost complete [33,52].
Another strength is the way alcohol consumption and ciga-
rette smoking was assessed in the NLCS. The detailed
assessment enabled us to evaluate associations between
endometrial cancer and various measures of both exposures.
Furthermore,wewereabletocontrolforconfoundingbythe
most important risk factors of endometrial cancer [40].
To sum up our major ﬁndings, we found that alcohol
consumption is not associated with endometrial cancer.
Current smoking was associated with a reduced risk of
endometrial cancer in postmenopausal women. This asso-
ciation was probably not mediated by a decreased BMI or
by an earlier age at menopause. Larger prospective studies
with information on the type of HRT are needed in order to
investigate possible effect modiﬁcation by different types
of HRT.
Possibly, the incidence of endometrial cancer could be
reduced if smoking was more common in female popula-
tions; however, such a reduction would be overshadowed
by a dramatically increasing incidence of many other
chronic diseases. Thus, individuals should still be encour-
aged to quit or not to start smoking.
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